Merad, M. & Martin, J. C. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat. Rev. Immunol. 20, 355–362 (2020).
Carvalho, T., Krammer, F. & Iwasaki, A. The first 12 months of COVID-19: a timeline of immunological insights. Nat. Rev. Immunol. 21, 245–256 (2021).
Mallah, S. I. et al. COVID-19: breaking down a global health crisis. Ann. Clin. Microbiol. Antimicrob. 20, 35 (2021).
Aleksova, A. et al. Effects of SARS-CoV-2 on cardiovascular system: the dual role of angiotensin-converting enzyme 2 (ACE2) as the virus receptor and homeostasis regulator-review. Int. J. Mol. Sci. 22, 4526 (2021).
Godeau, D., Petit, A., Richard, I., Roquelaure, Y. & Descatha, A. Return-to-work, disabilities and occupational health in the age of COVID-19. Scand. J. Work Environ. Health 47, 408–409 (2021).
Iwasaki, M. et al. Inflammation triggered by SARS-CoV-2 and ACE2 augment drives multiple organ failure of severe COVID-19: molecular mechanisms and implications. Inflammation 44, 13–34 (2021).
COvid-19 Multi-omics Blood ATlas (COMBAT) Consortium. A blood atlas of COVID-19 defines hallmarks of disease severity and specificity. Cell 185, 916–938.e958 (2022).
Zeng, J. et al. Specific inhibition of the NLRP3 inflammasome suppresses immune overactivation and alleviates COVID-19 like pathology in mice. EBioMedicine 75, 103803 (2022).
Acharya, D., Liu, G. & Gack, M. U. Dysregulation of type I interferon responses in COVID-19. Nat. Rev. Immunol. 20, 397–398 (2020).
V’Kovski, P., Kratzel, A., Steiner, S., Stalder, H. & Thiel, V. Coronavirus biology and replication: implications for SARS-CoV-2. Nat. Rev. Microbiol. 19, 155–170 (2021).
Ding, Y. et al. The clinical pathology of severe acute respiratory syndrome (SARS): a report from China. J. Pathol. 200, 282–289 (2003).
Kopecky-Bromberg, S. A., Martinez-Sobrido, L. & Palese, P. 7a protein of severe acute respiratory syndrome coronavirus inhibits cellular protein synthesis and activates p38 mitogen-activated protein kinase. J. Virol. 80, 785–793 (2006).
Tan, Y. X. et al. Induction of apoptosis by the severe acute respiratory syndrome coronavirus 7a protein is dependent on its interaction with the Bcl-XL protein. J. Virol. 81, 6346–6355 (2007).
Tsoi, H. et al. The SARS-coronavirus membrane protein induces apoptosis via interfering with PDK1-PKB/Akt signalling. Biochem. J. 464, 439–447 (2014).
Pasparakis, M. & Vandenabeele, P. Necroptosis and its role in inflammation. Nature 517, 311–320 (2015).
Zhu, H., Santo, A., Jia, Z. & Robert Li, Y. GPx4 in bacterial infection and polymicrobial sepsis: involvement of ferroptosis and pyroptosis. React. Oxyg. Species 7, 154–160 (2019).
Zille, M. et al. Neuronal death after hemorrhagic stroke in vitro and in vivo shares features of ferroptosis and necroptosis. Stroke 48, 1033–1043 (2017).
Donia, A. & Bokhari, H. Apoptosis induced by SARS-CoV-2: can we target it? Apoptosis 26, 7–8 (2021).
Mahtarin, R. et al. Structure and dynamics of membrane protein in SARS-CoV-2. J. Biomol. Struct. Dyn. 40, 4725–4738 (2022).
Llambi, F. et al. BOK is a non-canonical BCL-2 family effector of apoptosis regulated by ER-associated degradation. Cell 165, 421–433 (2016).
Yang, Y. et al. SARS-CoV-2 membrane protein causes the mitochondrial apoptosis and pulmonary edema via targeting BOK. Cell Death Differ. 29, 1395–1408 (2022).
Li, X., Zhang, Z., Wang, Z., Gutiérrez-Castrellón, P. & Shi, H. Cell deaths: involvement in the pathogenesis and intervention therapy of COVID-19. Signal Transduct. Target. Ther. 7, 186 (2022).
Ren, Y. et al. SARS-CoV-2 membrane glycoprotein M triggers apoptosis with the assistance of nucleocapsid protein N in cells. Front. Cell. Infect. Microbiol. 11, 706252 (2021).
Carlson, C. R. et al. Phosphoregulation of phase separation by the SARS-CoV-2 N protein suggests a biophysical basis for its dual functions. Mol. Cell 80, 1092–1103.e1094 (2020).
Lan, J. et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 581, 215–220 (2020).
Ye, Q., West, A. M. V., Silletti, S. & Corbett, K. D. Architecture and self-assembly of the SARS-CoV-2 nucleocapsid protein. Protein Sci. 29, 1890–1901 (2020).
Zhu, Z. et al. Therapy targets SARS-CoV-2 infection-induced cell death. Front. Immunol. 13, 870216 (2022).
Chu, H. et al. Coronaviruses exploit a host cysteine-aspartic protease for replication. Nature 609, 785–792 (2022).
Sternberg, A. & Naujokat, C. Structural features of coronavirus SARS-CoV-2 spike protein: targets for vaccination. Life Sci. 257, 118056 (2020).
Jiang, Y. et al. ROS-dependent activation of autophagy through the PI3K/Akt/mTOR pathway is induced by hydroxysafflor yellow a-sonodynamic therapy in THP-1 macrophages. Oxid. Med. Cell. Longev. 2017, 8519169 (2017).
Vucicevic, L. et al. Compound C induces protective autophagy in cancer cells through AMPK inhibition-independent blockade of Akt/mTOR pathway. Autophagy 7, 40–50 (2011).
Eisenberg-Lerner, A., Bialik, S., Simon, H. U. & Kimchi, A. Life and death partners: apoptosis, autophagy and the cross-talk between them. Cell Death Differ. 16, 966–975 (2009).
Li, F. et al. SARS-CoV-2 spike promotes inflammation and apoptosis through autophagy by ROS-suppressed PI3K/AKT/mTOR signaling. Biochim. Biophys. Acta Mol. Basis Dis. 1867, 166260 (2021).
Barhoumi, T. et al. SARS-CoV-2 coronavirus spike protein-induced apoptosis, inflammatory, and oxidative stress responses in THP-1-like-macrophages: potential role of angiotensin-converting enzyme inhibitor (Perindopril). Front. Immunol. 12, 728896 (2021).
Wu, C. T. et al. SARS-CoV-2 infects human pancreatic β cells and elicits β cell impairment. Cell Metab. 33, 1565–1576.e1565 (2021).
Freundt, E. C. et al. The open reading frame 3a protein of severe acute respiratory syndrome-associated coronavirus promotes membrane rearrangement and cell death. J. Virol. 84, 1097–1109 (2010).
Law, P. T. W. et al. The 3a protein of severe acute respiratory syndrome-associated coronavirus induces apoptosis in Vero E6 cells. J. Gen. Virol. 86, 1921–1930 (2005).
Issa, E., Merhi, G., Panossian, B., Salloum, T. & Tokajian, S. SARS-CoV-2 and ORF3a: nonsynonymous mutations, functional domains, and viral pathogenesis. mSystems 5, e00266–20 (2020).
Bianchi, M., Borsetti, A., Ciccozzi, M. & Pascarella, S. SARS-Cov-2 ORF3a: mutability and function. Int. J. Biol. Macromol. 170, 820–826 (2021).
Kern, D. M. et al. Cryo-EM structure of SARS-CoV-2 ORF3a in lipid nanodiscs. Nat. Struct. Mol. Biol. 28, 573–582 (2021).
Zhang, X. et al. SARS-CoV-2 ORF3a induces RETREG1/FAM134B-dependent reticulophagy and triggers sequential ER stress and inflammatory responses during SARS-CoV-2 infection. Autophagy 18, 2576–2592 (2022).
Ren, Y. et al. The ORF3a protein of SARS-CoV-2 induces apoptosis in cells. Cell. Mol. Immunol. 17, 881–883 (2020).
Abdalla, A. E. et al. Insight into the emerging role of SARS-CoV-2 nonstructural and accessory proteins in modulation of multiple mechanisms of host innate defense. Bosn. J. Basic Med. Sci. 21, 515–527 (2021).
Zhou, Z. et al. Structural insight reveals SARS-CoV-2 ORF7a as an immunomodulating factor for human CD14(+) monocytes. iScience 24, 102187 (2021).
Arya, R. et al. Structural insights into SARS-CoV-2 proteins. J. Mol. Biol. 433, 166725 (2021).
Liu, Z. et al. Ubiquitination of SARS-CoV-2 ORF7a prevents cell death induced by recruiting BclXL to activate ER stress. Microbiol. Spectr. 10, e0150922 (2022).
Yang, R. et al. SARS-CoV-2 accessory protein ORF7b mediates tumor necrosis factor-α-induced apoptosis in cells. Front. Microbiol. 12, 654709 (2021).
Yuen, C. K. et al. SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists. Emerg. Microbes Infect. 9, 1418–1428 (2020).
Gordon, D. E. et al. Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms. Science 370, eabe9403 (2020).
Lin, R., Paz, S. & Hiscott, J. Tom70 imports antiviral immunity to the mitochondria. Cell Res. 20, 971–973 (2010).
Wei, B. et al. Tom70 mediates Sendai virus-induced apoptosis on mitochondria. J. Virol. 89, 3804–3818 (2015).
Liu, X. Y., Wei, B., Shi, H. X., Shan, Y. F. & Wang, C. Tom70 mediates activation of interferon regulatory factor 3 on mitochondria. Cell Res 20, 994–1011 (2010).
Jiang, H. W. et al. SARS-CoV-2 Orf9b suppresses type I interferon responses by targeting TOM70. Cell. Mol. Immunol. 17, 998–1000 (2020).
Lavrik, I. N. & Krammer, P. H. Regulation of CD95/Fas signaling at the DISC. Cell Death Differ. 19, 36–41 (2012).
Nilsson-Payant, B. E. et al. The NF-κB transcriptional footprint is essential for SARS-CoV-2 replication. J. Virol. 95, e0125721 (2021).
Kucharczak, J., Simmons, M. J., Fan, Y. & Gélinas, C. To be, or not to be: NF-kappaB is the answer-role of Rel/NF-kappaB in the regulation of apoptosis. Oncogene 22, 8961–8982 (2003).
Gordon, D. E. et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature 583, 459–468 (2020).
Khan, S. et al. SARS-CoV-2 spike protein induces inflammation via TLR2-dependent activation of the NF-κB pathway. Elife 10, e68563 (2021).
Feng, Y. et al. COVID-19 with different severities: a multicenter study of clinical features. Am. J. Respir. Crit. Care Med. 201, 1380–1388 (2020).
Karki, R. et al. Synergism of TNF-α and IFN-γ triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes. Cell 184, 149–168.e117 (2021).
Mahdizadeh, S. J., Thomas, M. & Eriksson, L. A. Reconstruction of the fas-based death-inducing signaling complex (DISC) using a protein-protein docking meta-approach. J. Chem. Inf. Model. 61, 3543–3558 (2021).
Irmler, M. et al. Inhibition of death receptor signals by cellular FLIP. Nature 388, 190–195 (1997).
Hillert, L. K. et al. Dissecting DISC regulation via pharmacological targeting of caspase-8/c-FLIP(L) heterodimer. Cell Death Differ. 27, 2117–2130 (2020).
Hachem, H. et al. Rapid and sustained decline in CXCL-10 (IP-10) annotates clinical outcomes following TNFα-antagonist therapy in hospitalized patients with severe and critical COVID-19 respiratory failure. J. Clin. Transl. Sci. 5, e146 (2021).
Leone, G. M., Mangano, K., Petralia, M. C., Nicoletti, F. & Fagone, P. Past, present and (foreseeable) future of biological anti-TNF alpha therapy. J. Clin. Med. 12, 1630 (2023).
Gracia-Sancho, J. et al. Emricasan ameliorates portal hypertension and liver fibrosis in cirrhotic rats through a hepatocyte-mediated paracrine mechanism. Hepatol. Commun. 3, 987–1000 (2019).
Plassmeyer, M. et al. Caspases and therapeutic potential of caspase inhibitors in moderate-severe SARS-CoV-2 infection and long COVID. Allergy 77, 118–129 (2022).
André, S. et al. T cell apoptosis characterizes severe covid-19 disease. Cell Death Differ. 29, 1486–1499 (2022).
Dong, Y. et al. A retrospective study of Pupingqinghua prescription versus Lianhuaqingwen in Chinese participants infected with SARS-CoV-2 omicron variants. Front. Pharmacol. 13, 988524 (2022).
Runfeng, L. et al. Corrigendum to: Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2) [Pharmacol. Res. 156 (2020) 104761]. Pharmacol. Res. 174, 105907 (2021).
Yang, R. et al. Mechanisms underlying the effects of lianhua qingwen on sepsis-induced acute lung injury: a network pharmacology approach. Front. Pharmacol. 12, 717652 (2021).
Zhao, J. et al. Systems pharmacological study illustrates the immune regulation, anti-infection, anti-inflammation, and multi-organ protection mechanism of Qing-Fei-Pai-Du decoction in the treatment of COVID-19. Phytomedicine 85, 153315 (2021).
Hanta, I., Cilli, A. & Sevinc, C. The effectiveness, safety, and tolerability of pirfenidone in idiopathic pulmonary fibrosis: a retrospective study. Adv. Ther. 36, 1126–1131 (2019).
Chen, X. et al. Pyroptosis is driven by non-selective gasdermin-D pore and its morphology is different from MLKL channel-mediated necroptosis. Cell Res. 26, 1007–1020 (2016).
Hadjadj, J. et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science 369, 718–724 (2020).
Duprez, L. et al. RIP kinase-dependent necrosis drives lethal systemic inflammatory response syndrome. Immunity 35, 908–918 (2011).
Xu, G. et al. SARS-CoV-2 promotes RIPK1 activation to facilitate viral propagation. Cell Res. 31, 1230–1243 (2021).
Zhang, J. et al. Understanding the role of SARS-CoV-2 ORF3a in viral pathogenesis and COVID-19. Front. Microbiol. 13, 854567 (2022).
Rothan, H. A. et al. SARS-CoV-2 infects primary neurons from human ACE2 expressing mice and upregulates genes involved in the inflammatory and necroptotic pathways. Pathogens 11, 257 (2022).
Frühbeck, G. et al. FNDC4 and FNDC5 reduce SARS-CoV-2 entry points and spike glycoprotein S1-induced pyroptosis, apoptosis, and necroptosis in human adipocytes. Cell. Mol. Immunol. 18, 2457–2459 (2021).
Santos, L. D. et al. SARS-CoV-2 immune complex triggers human monocyte necroptosis. Int. Immunopharmacol. 117, 109954 (2023).
Ferren, M. et al. Hamster organotypic modeling of SARS-CoV-2 lung and brainstem infection. Nat. Commun. 12, 5809 (2021).
Riebeling, T. et al. Primidone blocks RIPK1-driven cell death and inflammation. Cell Death Differ. 28, 1610–1626 (2021).
Chen, S. et al. RIPK1/RIPK3/MLKL-mediated necroptosis contributes to compression-induced rat nucleus pulposus cells death. Apoptosis 22, 626–638 (2017).
Wang, X. et al. RNA viruses promote activation of the NLRP3 inflammasome through a RIP1-RIP3-DRP1 signaling pathway. Nat. Immunol. 15, 1126–1133 (2014).
Fink, S. L. & Cookson, B. T. Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells. Infect. Immun. 73, 1907–1916 (2005).
Jorgensen, I. & Miao, E. A. Pyroptotic cell death defends against intracellular pathogens. Immunol. Rev. 265, 130–142 (2015).
Van Opdenbosch, N. & Lamkanfi, M. Caspases in cell death, inflammation, and disease. Immunity 50, 1352–1364 (2019).
Kayagaki, N. et al. Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling. Nature 526, 666–671 (2015).
Broz, P., Pelegrín, P. & Shao, F. The gasdermins, a protein family executing cell death and inflammation. Nat. Rev. Immunol. 20, 143–157 (2020).
Freeman, T. L. & Swartz, T. H. Targeting the NLRP3 inflammasome in severe COVID-19. Front. Immunol. 11, 1518 (2020).
Theobald, S. J. et al. Long-lived macrophage reprogramming drives spike protein-mediated inflammasome activation in COVID-19. Embo. Mol. Med. 13, e14150 (2021).
Sun, X. et al. SARS-CoV-2 non-structural protein 6 triggers NLRP3-dependent pyroptosis by targeting ATP6AP1. Cell Death Differ. 29, 1240–1254 (2022).
Xu, H. et al. SARS-CoV-2 viroporin encoded by ORF3a triggers the NLRP3 inflammatory pathway. Virology 568, 13–22 (2022).
Bertoni, A. et al. Spontaneous NLRP3 inflammasome-driven IL-1-β secretion is induced in severe COVID-19 patients and responds to anakinra treatment. J. Allergy Clin. Immunol. 150, 796–805 (2022).
Kim, N.-E., Kim, D.-K. & Song, Y.-J. SARS-CoV-2 nonstructural proteins 1 and 13 suppress caspase-1 and the NLRP3 inflammasome activation. Microorganisms 9, 494 (2021).
Pan, P. et al. SARS-CoV-2 N protein promotes NLRP3 inflammasome activation to induce hyperinflammation. Nat. Commun. 12, 4664 (2021).
Ma, J. et al. SARS-CoV-2 nucleocapsid suppresses host pyroptosis by blocking Gasdermin D cleavage. EMBO J. 40, e108249 (2021).
Wu, Y. et al. RNA-induced liquid phase separation of SARS-CoV-2 nucleocapsid protein facilitates NF-κB hyper-activation and inflammation. Signal Transduct. Target. Ther. 6, 167 (2021).
Nishitsuji, H., Iwahori, S., Ohmori, M., Shimotohno, K. & Murata, T. Ubiquitination of SARS-CoV-2 NSP6 and ORF7a facilitates NF-κB Activation. MBio 13, e0097122 (2022).
Shi, F. et al. Coronaviruses Nsp5 antagonizes porcine gasdermin D-mediated pyroptosis by cleaving pore-forming p30 Fragment. MBio 13, e0273921 (2022).
Zheng, M. et al. TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines. Nat. Immunol. 22, 829–838 (2021).
Rosa-Fernandes, L. et al. SARS-CoV-2 activates ER stress and Unfolded protein response. Preprint at https://www.biorxiv.org/content/10.1101/2021.06.21.449284v1 (2021).
Quagliariello, V. et al. SARS-CoV-2 infection: NLRP3 inflammasome as plausible target to prevent cardiopulmonary complications? Eur. Rev. Med. Pharmacol. Sci. 24, 9169–9171 (2020).
Hu, J. J. et al. FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation. Nat. Immunol. 21, 736–745 (2020).
Duarte, M. et al. Telmisartan for treatment of Covid-19 patients: an open multicenter randomized clinical trial. EClinicalMedicine 37, 100962 (2021).
Xiong, S. et al. Interleukin-1RA mitigates SARS-CoV-2-induced inflammatory lung vascular leakage and mortality in humanized K18-hACE-2 Mice. Arterioscler. Thromb. Vasc. Biol. 41, 2773–2785 (2021).
Katia, F. et al. Efficacy of canakinumab in mild or severe COVID-19 pneumonia. Immun. Inflamm. Dis. 9, 399–405 (2021).
Potere, N. et al. The role of IL-6 and IL-6 blockade in COVID-19. Expert Rev. Clin. Immunol. 17, 601–618 (2021).
Gordon, A. C. et al. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N. Engl. J. Med. 384, 1491–1502 (2021).
Perez, M. A., Magtanong, L., Dixon, S. J. & Watts, J. L. Dietary lipids induce ferroptosis in caenorhabditiselegans and human cancer cells. Dev. Cell 54, 447–454 (2020).
Yang, W. S. et al. Regulation of ferroptotic cancer cell death by GPX4. Cell 156, 317–331 (2014).
Ge, C. et al. Emerging mechanisms and disease implications of ferroptosis: potential applications of natural products. Front. Cell Dev. Biol. 9, 774957 (2021).
Jacobs, W. et al. Fatal lymphocytic cardiac damage in coronavirus disease 2019 (COVID-19): autopsy reveals a ferroptosis signature. ESC Heart Fail. 7, 3772–3781 (2020).
Zhao, K. et al. Serum iron level as a potential predictor of coronavirus disease 2019 severity and mortality: a retrospective study. Open Forum Infect. Dis. 7, ofaa250 (2020).
Mehta, P. et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395, 1033–1034 (2020).
Banchini, F., Vallisa, D., Maniscalco, P. & Capelli, P. Iron overload and Hepcidin overexpression could play a key role in COVID infection, and may explain vulnerability in elderly, diabetics, and obese patients. Acta Biomed. 91, e2020013 (2020).
Tang, S. et al. The role of iron, its metabolism and ferroptosis in traumatic brain injury. Front. Cell. Neurosci. 14, 590789 (2020).
Edeas, M., Saleh, J. & Peyssonnaux, C. Iron: innocent bystander or vicious culprit in COVID-19 pathogenesis? Int. J. Infect. Dis. 97, 303–305 (2020).
Wang, Y. et al. SARS-CoV-2 suppresses mRNA expression of selenoproteins associated with ferroptosis, endoplasmic reticulum stress and DNA synthesis. Food Chem. Toxicol. 153, 112286 (2021).
Mitra, J. et al. SARS-CoV-2 and the central nervous system: emerging insights into hemorrhage-associated neurological consequences and therapeutic considerations. Ageing Res. Rev. 80, 101687 (2022).
Huang, L. et al. Dynamic blood single-cell immune responses in patients with COVID-19. Signal Transduct. Target. Ther. 6, 110 (2021).
Bartolini, D. et al. SARS-CoV2 infection impairs the metabolism and redox function of cellular glutathione. Redox Biol. 45, 102041 (2021).
Kumar, P. et al. Severe glutathione deficiency, oxidative stress and oxidant damage in adults hospitalized with COVID-19: implications for GlyNAC (Glycine and N-Acetylcysteine) supplementation. Antioxidants 11, 50 (2021).
Cheng, Y. et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 97, 829–838 (2020).
Ronco, C., Reis, T. & Husain-Syed, F. Management of acute kidney injury in patients with COVID-19. Lancet Respir. Med. 8, 738–742 (2020).
Han, Y. et al. SARS-CoV-2 infection induces ferroptosis of sinoatrial node pacemaker cells. Circ. Res. 130, 963–977 (2022).
Garrick, M. D. & Ghio, A. J. Iron chelation may harm patients with COVID-19. Eur. J. Clin. Pharmacol. 77, 265–266 (2021).
Yang, L. et al. Tocilizumab mimotope alleviates kidney injury and fibrosis by inhibiting IL-6 signaling and ferroptosis in UUO model. Life Sci. 261, 118487 (2020).
Zhang, J., Taylor, E. W., Bennett, K., Saad, R. & Rayman, M. P. Association between regional selenium status and reported outcome of COVID-19 cases in China. Am. J. Clin. Nutr. 111, 1297–1299 (2020).
Moghaddam, A. et al. Selenium deficiency is associated with mortality risk from COVID-19. Nutrients 12, 2098 (2020).
Kieliszek, M. & Lipinski, B. Selenium supplementation in the prevention of coronavirus infections (COVID-19). Med. Hypotheses 143, 109878 (2020).
Alim, I. et al. Selenium drives a transcriptional adaptive program to block ferroptosis and treat stroke. Cell 177, 1262–1279.e25 (2019).
Jin, Z. et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature 582, 289–293 (2020).
Bermano, G., Méplan, C., Mercer, D. K. & Hesketh, J. E. Selenium and viral infection: are there lessons for COVID-19? Br. J. Nutr. 125, 618–627 (2021).
Han, F., Li, S., Yang, Y. & Bai, Z. Interleukin-6 promotes ferroptosis in bronchial epithelial cells by inducing reactive oxygen species-dependent lipid peroxidation and disrupting iron homeostasis. Bioengineered 12, 5279–5288 (2021).
Gupta, G. et al. Cobalt nanoparticles trigger ferroptosis-like cell death (oxytosis) in neuronal cells: potential implications for neurodegenerative disease. FASEB J. 34, 5262–5281 (2020).
Miotto, G. et al. Insight into the mechanism of ferroptosis inhibition by ferrostatin-1. Redox Biol. 28, 101328 (2020).
Li, J. et al. Ferroptosis: past, present and future. Cell Death Dis. 11, 88 (2020).
Douda, D. N., Yip, L., Khan, M. A., Grasemann, H. & Palaniyar, N. Akt is essential to induce NADPH-dependent NETosis and to switch the neutrophil death to apoptosis. Blood 123, 597–600 (2014).
Douda, D. N., Khan, M. A., Grasemann, H. & Palaniyar, N. SK3 channel and mitochondrial ROS mediate NADPH oxidase-independent NETosis induced by calcium influx. Proc. Natl Acad. Sci. USA 112, 2817–2822 (2015).
Li, P. et al. PAD4 is essential for antibacterial innate immunity mediated by neutrophil extracellular traps. J. Exp. Med 207, 1853–1862 (2010).
Raftery, M. J. et al. β2 integrin mediates hantavirus-induced release of neutrophil extracellular traps. J. Exp. Med. 211, 1485–1497 (2014).
Saitoh, T. et al. Neutrophil extracellular traps mediate a host defense response to human immunodeficiency virus-1. Cell Host Microbe 12, 109–116 (2012).
Jenne, C. N. et al. Neutrophils recruited to sites of infection protect from virus challenge by releasing neutrophil extracellular traps. Cell Host Microbe 13, 169–180 (2013).
Tamassia, N. et al. Cytokine production by human neutrophils: revisiting the “dark side of the moon”. Eur. J. Clin. Invest. 48, e12952 (2018).
Park, J. H. & Lee, H. K. Re-analysis of single cell transcriptome reveals that the NR3C1-CXCL8-neutrophil axis determines the severity of COVID-19. Front. Immunol. 11, 2145 (2020).
Yaqinuddin, A. & Kashir, J. Novel therapeutic targets for SARS-CoV-2-induced acute lung injury: targeting a potential IL-1β/neutrophil extracellular traps feedback loop. Med. Hypotheses 143, 109906 (2020).
Kaiser, R. et al. Self-sustaining IL-8 loops drive a prothrombotic neutrophil phenotype in severe COVID-19. JCI Insight 6, e150862 (2021).
Zhu, Y., Chen, X. & Liu, X. NETosis and neutrophil extracellular traps in COVID-19: immunothrombosis and beyond. Front. Immunol. 13, 838011 (2022).
LaSalle, T. J. et al. Longitudinal characterization of circulating neutrophils uncovers phenotypes associated with severity in hospitalized COVID-19 patients. Cell Rep. Med. 3, 100779 (2022).
Veras, F. P. et al. SARS-CoV-2-triggered neutrophil extracellular traps mediate COVID-19 pathology. J. Exp. Med. 217, e20201129 (2020).
Arcanjo, A. et al. The emerging role of neutrophil extracellular traps in severe acute respiratory syndrome coronavirus 2 (COVID-19). Sci. Rep. 10, 19630 (2020).
Beltrán-García, J. et al. Oxidative stress and inflammation in COVID-19-associated sepsis: the potential role of anti-oxidant therapy in avoiding disease progression. Antioxidants 9, 936 (2020).
Rahman, N. et al. Virtual screening of natural products against type ii transmembrane serine protease (TMPRSS2), the priming agent of coronavirus 2 (SARS-CoV-2). Molecules 25, 2271 (2020).
Hong, W. et al. Histones released by NETosis enhance the infectivity of SARS-CoV-2 by bridging the spike protein subunit 2 and sialic acid on host cells. Cell. Mol. Immunol. 19, 577–587 (2022).
Aymonnier, K. et al. Inflammasome activation in neutrophils of patients with severe COVID-19. Blood Adv. 6, 2001–2013 (2022).
Maki, C. et al. Evaluation of appropriate indications for the use of sivelestat sodium in acute respiratory distress syndrome: a retrospective cohort study. Acute Med. Surg. 7, e471 (2020).
Arisan, E. D., Uysal-Onganer, P. & Lange, S. Putative roles for peptidylarginine deiminases in COVID-19. Int. J. Mol. Sci. 21, 4662 (2020).
Elliott, W. Jr. et al. PAD inhibitors as a potential treatment for SARS-CoV-2 immunothrombosis. Biomedicines 9, 1867 (2021).
Thangaraju, P., Ty, S. S., Reddy L, S. S. & Sasanka, K. S. B. S. K. Repurposing thalidomide, its analogue and apremilast for possible antiviral in situation of severe covid cytokine syndrome. Infect. Disord. Drug Targets 22, 84–94 (2022).
Gavriilidis, E. et al. Combined administration of inhaled DNase, baricitinib and tocilizumab as rescue treatment in COVID-19 patients with severe respiratory failure. Clin. Immunol. 238, 109016 (2022).
Adrover, J. M. et al. Disulfiram inhibits neutrophil extracellular trap formation and protects rodents from acute lung injury and SARS-CoV-2 infection. JCI Insight 7, e157342 (2022).
Silva, C. M. S. et al. Gasdermin-D activation by SARS-CoV-2 triggers NET and mediate COVID-19 immunopathology. Crit. Care 26, 206 (2022).
Hamam, H. J. & Palaniyar, N. Post-translational modifications in NETosis and NETs-mediated diseases. Biomolecules 9, 369 (2019).
Janiuk, K., Jabłońska, E. & Garley, M. Significance of NETs formation in COVID-19. Cells 10, 151 (2021).
Ackermann, M. et al. Patients with COVID-19: in the dark-NETs of neutrophils. Cell Death Differ. 28, 3125–3139 (2021).
Gómez, R. M., López Ortiz, A. O. & Schattner, M. Platelets and extracellular traps in infections. Platelets 32, 305–313 (2021).
Sung, P. S. & Hsieh, S. L. C-type lectins and extracellular vesicles in virus-induced NETosis. J. Biomed. Sci. 28, 46 (2021).
Lee, Y. Y. et al. Long-acting nanoparticulate DNase-1 for effective suppression of SARS-CoV-2-mediated neutrophil activities and cytokine storm. Biomaterials 267, 120389 (2021).
Liu, X. et al. Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19. Acta Pharm. Sin. B 10, 1205–1215 (2020).
Maldonado, V. et al. Pentoxifylline decreases serum LDH levels and increases lymphocyte count in COVID-19 patients: results from an external pilot study. Int. Immunopharmacol. 90, 107209 (2021).
Liu, Y. et al. The role of neutrophil elastase in aortic valve calcification. J. Transl. Med. 20, 167 (2022).
Ma, H. et al. Pyroptosis of syncytia formed by fusion of SARS-CoV-2 spike and ACE2-expressing cells. Cell Discov. 7, 73 (2021).
Chu, H. et al. Targeting highly pathogenic coronavirus-induced apoptosis reduces viral pathogenesis and disease severity. Sci. Adv. 7, eabf8577 (2021).
Lobo-Galo, N., Terrazas-López, M., Martínez-Martínez, A. & Díaz-Sánchez, Á. G. FDA-approved thiol-reacting drugs that potentially bind into the SARS-CoV-2 main protease, essential for viral replication. J. Biomol. Struct. Dyn. 39, 3419–3427 (2021).
The mention sources can contact us to remove/changing this article
What Are The Main Benefits Of Comparing Car Insurance Quotes Online
LOS ANGELES, CA / ACCESSWIRE / June 24, 2020, / Compare-autoinsurance.Org has launched a new blog post that presents the main benefits of comparing multiple car insurance quotes. For more info and free online quotes, please visit https://compare-autoinsurance.Org/the-advantages-of-comparing-prices-with-car-insurance-quotes-online/ The modern society has numerous technological advantages. One important advantage is the speed at which information is sent and received. With the help of the internet, the shopping habits of many persons have drastically changed. The car insurance industry hasn't remained untouched by these changes. On the internet, drivers can compare insurance prices and find out which sellers have the best offers. View photos The advantages of comparing online car insurance quotes are the following: Online quotes can be obtained from anywhere and at any time. Unlike physical insurance agencies, websites don't have a specific schedule and they are available at any time. Drivers that have busy working schedules, can compare quotes from anywhere and at any time, even at midnight. Multiple choices. Almost all insurance providers, no matter if they are well-known brands or just local insurers, have an online presence. Online quotes will allow policyholders the chance to discover multiple insurance companies and check their prices. Drivers are no longer required to get quotes from just a few known insurance companies. Also, local and regional insurers can provide lower insurance rates for the same services. Accurate insurance estimates. Online quotes can only be accurate if the customers provide accurate and real info about their car models and driving history. Lying about past driving incidents can make the price estimates to be lower, but when dealing with an insurance company lying to them is useless. Usually, insurance companies will do research about a potential customer before granting him coverage. Online quotes can be sorted easily. Although drivers are recommended to not choose a policy just based on its price, drivers can easily sort quotes by insurance price. Using brokerage websites will allow drivers to get quotes from multiple insurers, thus making the comparison faster and easier. For additional info, money-saving tips, and free car insurance quotes, visit https://compare-autoinsurance.Org/ Compare-autoinsurance.Org is an online provider of life, home, health, and auto insurance quotes. This website is unique because it does not simply stick to one kind of insurance provider, but brings the clients the best deals from many different online insurance carriers. In this way, clients have access to offers from multiple carriers all in one place: this website. On this site, customers have access to quotes for insurance plans from various agencies, such as local or nationwide agencies, brand names insurance companies, etc. "Online quotes can easily help drivers obtain better car insurance deals. All they have to do is to complete an online form with accurate and real info, then compare prices", said Russell Rabichev, Marketing Director of Internet Marketing Company. CONTACT: Company Name: Internet Marketing CompanyPerson for contact Name: Gurgu CPhone Number: (818) 359-3898Email: [email protected]: https://compare-autoinsurance.Org/ SOURCE: Compare-autoinsurance.Org View source version on accesswire.Com:https://www.Accesswire.Com/595055/What-Are-The-Main-Benefits-Of-Comparing-Car-Insurance-Quotes-Online View photos
to request, modification Contact us at Here or [email protected]
- Less stuff, happier life
- Mosquito-borne disease risk looms for UK
- A taste of Portland, Maine
- Meta launches interactive Holocaust education tool using AI – BBC News
- Gaza: Israel orders civilians to flee “difficult fighting” in centre of Khan Younis
- Study explores the intricate gut-brain-liver connection and its impact on health
- Caroline Kennedy speaks about the JFK legacy
- How to write a bestselling novel with author Ken Follett | BBC News
- WHO’s Executive Board adopts resolution on access for life-saving aid into Gaza and respect for laws of war
- Study links organic Mediterranean diet to improved male fertility
- School lunch: Is $1.50 a child enough?
- UN warns half of Gaza’s population is starving – BBC News